logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Rigosertib for myelodysplastic syndrome – second line

< Back

Rigosertib for myelodysplastic syndrome – second line

Drugs

Cancer and Palliative Care

May 2020


Rigosertib is in clinical development for the treatment of high-risk myelodysplastic syndrome (MDS) in patients who had progressed on, failed to respond to, or relapsed after previous treatment with azacitidine or decitabine. MDS are a group of disorders in which red blood cells, white blood cells, and platelets produced by the bone marrow do not grow and mature normally. MDS are long-term debilitating and life-threatening diseases. MDS can lead to severe anaemia, infections or bleeding and can result in leukaemia (cancer of the white blood cells). MDS patients may require repeated blood transfusions and currently have few treatment options.

Rigosertib is administered intravenously and has been designed to inhibit and block the activity of various proteins that suppresses the growth of cancer cells. If licensed, rigosertib will provide a treatment option for higher-risk MDS patients who had progressed on, failed to respond to, or relapsed after previous treatment with azacitidine or decitabine.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts